In a phase IIa trial, a single systemic dose of etokimab, an IgG1 monoclonal antibody against IL-33, provided rapid and sustained clinical benefits in 12 adult patients with moderate to severe AD (26). The gene discussed is IL33; the disease is Alzheimer disease.